SpliceBio S.L.

https://www.splice.bio

LinkedIn: https://www.linkedin.com/company/splicebio

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. The Company’s proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio’s platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. *

	Start	2020-09-15 renamed
	Industry	gene therapy
	Industry 2	adeno-associated viral vector (AAV vector)

	Region	Barcelona
	Country	Spain (España)
	Street	10 Baldiri Reixac Parc Científic de Barcelona
	City	08028 Barcelona
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: SpliceBio S.L.. (2/16/22). "Press Release: SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline". Barcelona.

		Record changed: 2023-10-26

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for SpliceBio S.L.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)